Tags : Personalized Patients

Takeda Reports Updated Results of Adynovate in P-IIIb/IV PROPEL Study

Shots: The P-IIIb/IV PROPEL study involves assessing of Adynovate in prophylaxis targeting two different FVIII trough levels (1–3% REF/ 8–12% ELE) in prior treated patients with severe hemophilia A The P-IIIb/IV PROPEL study resulted in enhancing a patient’s PK profile by targeting ELE vs REF, patients with zero bleed (62% vs % vs 42%), reduction […]Read More